Venus Remedies Ltd’s Volatile Week: 0.01% Gain Amid Circuit Hits and Mixed Technical Signals

09 February 2026: Lower Circuit Hit Amid Heavy Selling Pressure

Venus Remedies Ltd experienced a significant setback on 09 Feb 2026, plunging 3.48% to close at Rs.713.15. The stock hit its lower circuit limit intraday, falling to a low of Rs.697.75, reflecting intense selling pressure. This marked the continuation of a seven-day losing streak, with the stock cumulatively down 11.56% over that period. The decline was starkly at odds with the broader market, as the Sensex rose 1.04% and the Pharmaceuticals & Biotechnology sector gained 1.31% that day.

The trading volume was modest at 2,271 shares, consistent with the stock’s micro-cap status and liquidity constraints. Technical indicators showed the stock trading below its short-term moving averages, signalling near-term weakness, although it remained above its 100-day and 200-day averages, suggesting some long-term support. The drop in delivery volumes by 46.58% indicated that the selling pressure was likely driven by short-term traders rather than sustained institutional exits.

10 February 2026: Upper Circuit Triggered on Strong Buying Interest

In a dramatic reversal, Venus Remedies surged 5.00% on 10 Feb 2026, hitting the upper circuit at Rs.748.80. This rally outpaced the sector’s 0.25% gain and the Sensex’s 0.25% rise, highlighting renewed investor enthusiasm. The stock traded in a range of Rs.707.00 to Rs.745.20, with a total volume of 1,230 shares and turnover of approximately Rs.1.13 crore. Despite the strong price gain, the weighted average price suggested cautious participation, with many trades occurring near the lower end of the day’s range.

The upper circuit triggered a regulatory freeze, halting further trading and signalling unfilled demand. This event marked a technical rebound after the prior week’s decline, though delivery volumes remained subdued, indicating speculative buying rather than broad-based accumulation. The stock’s Mojo Score improved to 77.0 with a 'Buy' rating, albeit downgraded from 'Strong Buy' earlier in the month, reflecting tempered optimism.

Technical Momentum Shifts Amid Mixed Market Signals

Also on 10 Feb 2026, technical analysis revealed a nuanced picture for Venus Remedies. Despite the intraday volatility and price swings, the stock’s overall technical momentum shifted from mildly bullish to bullish. Key indicators such as weekly and monthly KST (Know Sure Thing) and Dow Theory signals were positive, supporting a medium- to long-term upward trend.

However, the weekly MACD remained mildly bearish, reflecting short-term consolidation or selling pressure. The RSI hovered in neutral territory, indicating the stock was neither overbought nor oversold. Bollinger Bands suggested contained volatility within an upward channel, while On-Balance Volume showed bullish momentum on monthly charts but no clear weekly trend.

Venus Remedies’ historical returns remain impressive, with a 1-year gain of 98.07% compared to Sensex’s 7.97%, and a 10-year return of 577.90% versus Sensex’s 249.97%. Yet, recent short-term returns have been weaker, with a 1-week loss of 10.07% contrasting the Sensex’s 2.94% gain, underscoring the current consolidation phase.

13 February 2026: Week Closes Nearly Flat Amid Market Weakness

On the final trading day of the week, Venus Remedies declined 3.08% to close at Rs.739.00, a negligible net change of +0.01% for the week from Rs.738.90. This contrasted with the Sensex’s sharper 1.40% drop to 36,532.48, highlighting the stock’s relative stability. The volume was thin at 331 shares, reflecting subdued investor participation as the market digested the week’s volatility and awaited fresh catalysts.

Key Takeaways from the Week

1. Volatility and Circuit Triggers: The week was marked by extreme intraday volatility, with Venus Remedies hitting both lower and upper circuit limits on consecutive days. This reflects a market grappling with uncertainty and rapid shifts in investor sentiment.

2. Relative Outperformance: Despite the choppy price action, the stock outperformed the Sensex by 0.55% over the week, closing virtually flat while the benchmark declined. This suggests underlying resilience amid broader market weakness.

3. Mixed Technical Signals: Technical momentum shifted positively on monthly and weekly indicators, but short-term signals remain cautious. The divergence between price gains and delivery volumes points to speculative trading rather than broad accumulation.

4. Analyst Rating and Mojo Score: The stock’s Mojo Score of 77.0 and 'Buy' rating, downgraded from 'Strong Buy', indicate a tempered but constructive outlook. Investors should weigh technical rebounds against fundamental and liquidity considerations.

Conclusion

Venus Remedies Ltd’s trading week was a study in contrasts, with sharp declines followed by strong rebounds and regulatory circuit halts. The stock’s ability to close the week flat despite a volatile backdrop and a declining Sensex highlights its relative strength within the micro-cap pharmaceutical segment. However, the mixed technical signals and subdued delivery volumes counsel caution, suggesting that the stock remains in a consolidation phase rather than a confirmed breakout.

Investors should monitor upcoming sessions for confirmation of sustained momentum and volume support before considering fresh exposure. The company’s long-term fundamentals and sector tailwinds remain intact, but near-term price action will likely continue to reflect market sentiment and liquidity dynamics.

Unlock special upgrade rates for a limited period. Start Saving Now →